EGFR and non-small cell lung carcinoma: A study by Shimizu et al (15) demonstrated the difference on the distribution of EGFR mutations between primary tumors and metastatic lymph nodes (MLNs) in patients with resected NSCLC, and indicated that the EGFR mutation status of MLN is a predictive marker of the response to EGFR-TKI therapy.